+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "T Cell Therapies"

Malignant Mesothelioma - Pipeline Insight, 2024 - Product Thumbnail Image

Malignant Mesothelioma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 110 Pages
  • Global
From
Ewing Sarcoma - Pipeline Insight, 2024 - Product Thumbnail Image

Ewing Sarcoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 115 Pages
  • Global
From
Vulvar Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Vulvar Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 70 Pages
  • Global
From
Blastic Plasmacytoid Dendritic cell neoplasm - Pipeline Insight, 2024 - Product Thumbnail Image

Blastic Plasmacytoid Dendritic cell neoplasm - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 40 Pages
  • Global
From
Thymic Carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Thymic Carcinoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
CAR T-cell Therapy - Pipeline Insight, 2024 - Product Thumbnail Image

CAR T-cell Therapy - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
T-cell Surface Glycoprotein CD4 - Pipeline Insight, 2024 - Product Thumbnail Image

T-cell Surface Glycoprotein CD4 - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Anti-CD30 Therapies - Pipeline Insight, 2024 - Product Thumbnail Image

Anti-CD30 Therapies - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Anti-CD22 Therapies - Pipeline Insight, 2024 - Product Thumbnail Image

Anti-CD22 Therapies - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
NK Cell therapies - Pipeline Insight, 2024 - Product Thumbnail Image

NK Cell therapies - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 120 Pages
  • Global
From
Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2024 - Product Thumbnail Image

Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Anti-CD40 Antibody - Pipeline Insight, 2024 - Product Thumbnail Image

Anti-CD40 Antibody - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
CD3 antigen inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

CD3 antigen inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
TIM-3 Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

TIM-3 Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Antibody Drug Conjugate - Competitive landscape, 2023 - Product Thumbnail Image

Antibody Drug Conjugate - Competitive landscape, 2023

  • Report
  • November 2023
  • 650 Pages
  • Global
From
Global Cell Therapy Market 2024-2028 - Product Thumbnail Image

Global Cell Therapy Market 2024-2028

  • Report
  • August 2024
  • 166 Pages
  • Global
From
From
From
Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2024

  • Drug Pipelines
  • June 2024
  • 180 Pages
  • Global
From
Loading Indicator

T Cell Therapies are a type of biotechnology that involves the use of a patient's own T cells to treat diseases. T cells are a type of white blood cell that play a key role in the body's immune system. T Cell Therapies involve the extraction of T cells from a patient, engineering them to recognize and attack specific targets, and then reintroducing them into the patient's body. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. It has also been used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease. T Cell Therapies are a rapidly growing field of biotechnology, with many companies investing in research and development. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in developing and commercializing T Cell Therapies. Other companies, such as Gilead Sciences, Celgene, and Regeneron, are also investing in the field. Show Less Read more